The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial

• Main Authors: Apostolis Papaefthymiou (Author), Styliani Sarrou (Author), Konstantinos Pateras (Author), Ilias D. Vachliotis (Author), Georgios Agrotis (Author), Ioanna-Konstantina Sgantzou (Author), Georgios Perifanos (Author), Andreas Kapsoritakis (Author), Matthaios Speletas (Author), Marianna Vlychou (Author), George N. Dalekos (Author), Spyros Potamianos (Author), Antonis Goulas (Author), Jannis Kountouras (Author), Stergios A. Polyzos (Author)
• Format: Book
• Published: MDPI AG, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Biologic agents used in patients with inflammatory bowel diseases (IBD) may influence the pathophysiology of coexistent metabolic-dysfunction associated steatotic liver disease (MASLD). This study primarily aimed to evaluate the six-month effect of infliximab or vedolizumab vs. no biolog...